Nicotine Science and Policy

The FDA's proposed overhaul of its Premarket Tobacco Product Application (PMTA) process has renewed hopes for a more predictable regulatory pathway for vaping products in the United States.

Years of shifting scientific requirements, widespread application denials and regulatory uncertainty have created significant challenges for independent manufacturers. Industry representatives are now calling for clearer approval standards and a workable framework for flavoured e-cigarettes.

The proposed reforms could help strengthen the legal vaping market while supporting tobacco harm reduction. However, their success will depend on whether regulatory changes translate into timely, evidence-based decisions and improved access to lower-risk alternatives for adult smokers.

The US FDA is signalling a shift towards recognising the continuum of risk in tobacco and nicotine regulation.

At the Global Tobacco and Nicotine Forum in Lisbon, the agency outlined plans to accelerate product authorisations, reconsider its approach to flavoured e-cigarettes and improve communication about the relative risks of nicotine products.

The proposed changes also place greater emphasis on helping adults who smoke switch to lower-risk alternatives while maintaining safeguards against youth uptake. Integrating tobacco harm reduction into regulatory decisions could represent an important development in US tobacco control policy.

Smoking-related deaths in the United States remain concentrated among older adults, yet this population receives comparatively little attention in tobacco control research.

While teenage smoking has fallen to historic lows and youth vaping has declined substantially, smoking rates among older adults are improving more slowly.

The contrast raises important questions about research priorities and the allocation of public health resources. Greater attention to older smokers, effective cessation support and access to lower-risk nicotine alternatives could help address the population bearing the greatest burden of smoking-related disease.

Nicotine's future may extend beyond its traditional role as a smoking cessation aid. As cigarette use declines, a growing market for smoke-free nicotine products raises questions about consumer choice, regulation and the long-term place of nicotine in society.

A new policy analysis proposes a separate US regulatory framework for lower-risk consumer nicotine products, distinguishing them from combustible tobacco and medicinal nicotine.

The approach emphasises proportionate safety standards, accurate information and age restrictions, while recognising that tobacco harm reduction and informed adult consumer choice are related but distinct policy considerations.

Six weeks without cigarettes followed by a return to smoking should raise questions about what changed, rather than simply being recorded as an unsuccessful quit attempt.

Twelve key principles of tobacco harm reduction highlight the importance of understanding individual behaviour, access to affordable alternatives and the difference between trying a smoke-free product and switching completely.

The central message is that tobacco policy should measure meaningful outcomes, including sustained smoking cessation and reduced exposure to combustion, rather than relying solely on sales figures, restrictions or short-term statistics.